Readoutin 14d
Innovent Biologics (Suzhou) Co. Ltd. — IBI362
Phase 3 primary completion: IBI362 vs semaglutide in overweight or obese adults with MAFLD.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Overweight / MAFLD
Readoutin 14d
Phase 3 primary completion: IBI362 vs semaglutide in overweight or obese adults with MAFLD.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.